制药(BK4007)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK4007 制药

未开盘 03-10 16:00:00 EDT

857.96

-2.54

-0.29%

最高864.79	最低854.73	成交量3.26亿
今开860.49	昨收860.50	日振幅1.17%
总市值0.00	流通市值0.00	总股本0.00
成交额118.00亿	换手率--	流通股本0.00
市净率5.33149	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BK4007","market":"US","secType":"PLATE","nameCN":"制药","latestPrice":857.95776,"timestamp":1773172799999,"preClose":860.4951,"halted":0,"volume":326229340,"delay":0,"changeRate":-0.002949,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-2.537354,"latestTime":"03-10 16:00:00 EDT","open":860.4939,"high":864.79083,"low":854.7293,"amount":11799962523.906816,"amplitude":0.011693,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773235800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.33149,"peRate":26.056352,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK4007","defaultTab":"news","newsList":[{"id":"2618917262","title":"未来十年拟投资30亿美元！礼来在华加码布局口服减肥药产能","url":"https://stock-news.laohu8.com/highlight/detail?id=2618917262","media":"澎湃新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618917262?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:52","pubTimestamp":1773219157,"startTime":"0","endTime":"0","summary":"继2024年官宣苏州工厂产能升级后，礼来又在北京加码产能投资。3月11日，礼来宣布，计划未来十年累计投资30亿美元全面扩展在华供应链产能，打造口服固体制剂本土生产与供应体系，着力布局新一代口服小分子GLP-1受体激动剂orforglipron的生产能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603113668848354.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603113668848354.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SG9999014880.SGD","LU1127390331.HKD","IE00BFSS7M15.SGD","LU1917777945.USD","LU0106261372.USD","SG9999014898.SGD","LU0058720904.USD","LLYZ","LU0417517546.SGD","LU0787776722.HKD","GB00BDT5M118.USD","IE00B7KXQ091.USD","LU0672654240.SGD","LU2168563687.JPY","SG9999015986.USD","LU0238689110.USD","LLYX","LU2552382132.HKD","IE00BJJMRX11.SGD","LU2236285917.USD","BK4585","LU2237443549.SGD","LU2237443465.HKD","SGXZ99366536.SGD","LU2237443382.USD","SG9999001176.SGD","LU1023059063.AUD","LU2357305700.SGD","LU1623119135.USD","LU1551013342.USD","LU2552382058.USD","LU0823416689.USD","LU1720051017.SGD","SG9999015945.SGD","LU0006306889.USD","LU2213496289.HKD","IE00BKPKM429.USD","IE0004445015.USD","LU0689472784.USD","LU0882574055.USD","LU2491049909.HKD","LU0820561909.HKD","LU0353189680.USD","LU0820562030.AUD","LU0882574139.USD","LU0964807845.USD","LU2746668974.SGD","SG9999017495.SGD","LU1814569148.SGD","LU0889565916.HKD","LU2271345857.HKD","LU2361044949.HKD","LU0471298694.HKD","IE00BJLML261.HKD","LU0432979614.USD","LU0122379950.USD","LU1988902786.USD","IE00BFTCPJ56.SGD","IE00BKDWB100.SGD","SG9999015978.USD","LU0266013472.USD","LU0225283273.USD","LU1093756168.USD","LU2237438978.USD","LU2237443895.HKD","LU2023251221.USD","LU0203201768.USD","LU2087625088.SGD","LU1280957306.USD","LU2211815571.USD","LU1868837300.USD","LU2471134879.HKD","LU1629891620.HKD","LU1983299246.USD","LU2461242641.AUD","SG9999018865.SGD","SGXZ51526630.SGD","LU0158827948.USD","LU2089283258.USD","LU1366192091.USD","IE0005OL40V9.USD","LU0353189763.USD","LU0061475181.USD","LU0823434583.USD","IE00BN29S564.USD","LU1548497426.USD","LU2750360641.GBP","IE00BJJMRY28.SGD","LU0094547139.USD","LU1712237335.SGD","LU2112291526.USD","IE0002141913.USD","LU2456880835.USD","BK4599","LU2491050071.SGD","LU0823434740.USD","LU2028103732.USD","LU1064131342.USD","IE00B4R5TH58.HKD","LU0323591593.USD","LU1145028129.USD","LU1868836591.USD","SG9999014906.USD","LU1720051108.HKD","LU2168564149.EUR","LU2602419157.SGD","IE00B775H168.HKD","LU0320765059.SGD","LU1057294990.SGD","IE00BJT1NW94.SGD","LU2023250330.USD","LU2168564495.EUR","ELIS","LU2168564222.USD","LU0114720955.EUR","LLII","LU0234572021.USD","LU2264538146.SGD","LU1551013425.SGD","IE0009355771.USD","LU1093756325.SGD","BK4007","SG9999001176.USD","LU0203202063.USD","LU0385154629.USD","LU2324357040.USD","LU2896262040.SGD","LU2023250504.SGD","LU2756315664.SGD","LU0109391861.USD","LU1291159041.SGD","LU0471298777.SGD","LU1061106388.HKD","LU1323610961.USD","LLY","LU2111349929.HKD","LU2237443622.USD","LU2106854487.HKD","LU2471134796.USD","LU0109394709.USD","IE00BWXC8680.SGD","IE00BK4W5M84.HKD","LU0708995401.HKD","LU1267930730.SGD","IE00BK4W5L77.USD","LU2746668461.USD","IE00B1XK9C88.USD","LU2462157665.USD","SG9999015952.SGD","LU1232071149.USD","LU0354030438.USD","BK4588","LU2471134952.CNY","BK4533","LU0256863902.USD","LU0316494557.USD","LU0198837287.USD","ELIL","LU0456855351.SGD","LU0466842654.USD","LU0640476718.USD","SG9999018857.SGD","SGXZ57979304.SGD","LU1868836757.USD","LU0256863811.USD","IE0001KFT4U8.USD","BK4516","LU0096364046.USD","LU0786609619.USD","LU0158827781.USD","LU2063271972.USD","LU2468319806.SGD","SG9999013999.USD","LU2417539215.USD","IE00B1BXHZ80.USD","LU2552382215.SGD","LU0354030511.USD","LU2089984988.USD","LU0097036916.USD","IE00B2B36J28.USD","LU2108987350.USD","LU2265009873.SGD","IE0004445239.USD","LU0210536198.USD","SGXZ81514606.USD","BK4534","IE00BFSS8Q28.SGD","LU0320765992.SGD","LU1035775433.USD","LU1974910355.USD","LU2361044865.SGD","LU2471134523.USD","LU2360106947.USD","IE00BJJMRZ35.SGD","LU0683600562.USD","LU2168564065.EUR","LU1069344957.HKD","BK4581","LU0079474960.USD","SGXZ31699556.SGD","LU2361045086.USD","LU2750360997.AUD","LU0943347566.SGD","LU2756315318.SGD","IE00B4JS1V06.HKD","LU1804176565.USD","LU1989771016.USD","LU2237443978.SGD","LU0820561818.USD","LU1868837136.USD","LU2491050154.USD","LU2089284900.SGD","LU0289739699.SGD","LU1868836914.USD","SG9999014914.USD"],"gpt_icon":1},{"id":"2618891719","title":"礼来：计划未来十年累计投资30亿美元全面扩展在华供应链产能","url":"https://stock-news.laohu8.com/highlight/detail?id=2618891719","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618891719?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:47","pubTimestamp":1773218826,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4581","SG9999014898.SGD","SGXZ57979304.SGD","LU0320765992.SGD","IE00B7KXQ091.USD","LU2236285917.USD","SG9999001176.USD","LU0061475181.USD","SG9999015945.SGD","LU1548497426.USD","IE00BFTCPJ56.SGD","LU2112291526.USD","LU2361044865.SGD","LU1093756168.USD","LU2271345857.HKD","LU2461242641.AUD","IE00BFSS7M15.SGD","SG9999013999.USD","ELIS","LU0708995401.HKD","BK4533","LU1868836757.USD","LU0122379950.USD","LLY","LU0683600562.USD","LU1814569148.SGD","LU2023251221.USD","BK4585","LU2468319806.SGD","LU0210536198.USD","LU2324357040.USD","IE0002141913.USD","LU2462157665.USD","LU1366192091.USD","BK4516","LU1145028129.USD","LU0786609619.USD","LU2237438978.USD","LU2491050071.SGD","IE0009355771.USD","LU1093756325.SGD","LU2552382058.USD","IE00BN29S564.USD","IE00BJLML261.HKD","SGXZ31699556.SGD","LU1023059063.AUD","LU0320765059.SGD","IE00BJJMRZ35.SGD","SGXZ51526630.SGD","SG9999014914.USD","LU1629891620.HKD","IE00BK4W5M84.HKD","LU0109394709.USD","LU1868837136.USD","LU1804176565.USD","LU2264538146.SGD","LU0456855351.SGD","IE00B1BXHZ80.USD","LLII","LU1983299246.USD","LU1974910355.USD","IE00BKDWB100.SGD","LU2237443382.USD","LU2237443895.HKD","LU1720051017.SGD","LU2265009873.SGD","LU0820562030.AUD","SG9999015978.USD","SG9999014880.SGD","LU1057294990.SGD","LU2168564222.USD","LU2746668974.SGD","LU2361044949.HKD","LU0823434583.USD","LU1712237335.SGD","LU2106854487.HKD","LU2361045086.USD","SG9999001176.SGD","LU0354030438.USD","LU0289739699.SGD","IE00B4JS1V06.HKD","LU0432979614.USD","LU0158827781.USD","LU1551013425.SGD","LU2756315318.SGD","LU0079474960.USD","LU0943347566.SGD","IE00B1XK9C88.USD","LU1720051108.HKD","LU0385154629.USD","IE0005OL40V9.USD","LU2023250330.USD","LU2750360641.GBP","BK4007","LU1868837300.USD","LU1232071149.USD","BK4599","LU0471298777.SGD","LU0882574055.USD","LU2168564065.EUR","LU0353189680.USD","LU2237443465.HKD","SG9999015952.SGD","LU2023250504.SGD","LU2602419157.SGD","LU0097036916.USD","LU2896262040.SGD","LU2213496289.HKD","LU1988902786.USD","LU2063271972.USD","LU0466842654.USD","LU2750360997.AUD","LU1623119135.USD","ELIL","LU1291159041.SGD","IE00BJJMRY28.SGD","LU1280957306.USD","LU2471134523.USD","LU0058720904.USD","LU0158827948.USD","SG9999017495.SGD","LU0316494557.USD","LU1917777945.USD","LU2089283258.USD","IE00B4R5TH58.HKD","LU0820561818.USD","LU0354030511.USD","LU2089984988.USD","LU0787776722.HKD","LU1064131342.USD","LU2357305700.SGD","LU0094547139.USD","LU2471134952.CNY","LU2168564149.EUR","LU1061106388.HKD","LU0109391861.USD","LU0417517546.SGD","LU0006306889.USD","LU2471134879.HKD","LU2168563687.JPY","IE00BJT1NW94.SGD","IE00BFSS8Q28.SGD","IE00BJJMRX11.SGD","LU1035775433.USD","LU0823416689.USD","LLYZ","LU1989771016.USD","LU1868836591.USD","LU2211815571.USD","LU0964807845.USD","IE0004445239.USD","LU0471298694.HKD","SG9999014906.USD","LU0889565916.HKD","LU2756315664.SGD","IE00BWXC8680.SGD","IE00BK4W5L77.USD","LU0256863902.USD","LU2237443549.SGD","LU2028103732.USD","LU1868836914.USD","LU0256863811.USD","LU0353189763.USD","LU0672654240.SGD","LU2237443978.SGD","LU0820561909.HKD","LU2168564495.EUR","LU1551013342.USD","LU2087625088.SGD","LU2237443622.USD","BK4534","LU2552382215.SGD","SGXZ81514606.USD","LU0096364046.USD","LU0106261372.USD","LU2417539215.USD","LU2746668461.USD","SG9999018857.SGD","LU0203201768.USD","LU0640476718.USD","LU2471134796.USD","LU2552382132.HKD","LU0114720955.EUR","LU0203202063.USD","LU2360106947.USD","LU0238689110.USD","LU2456880835.USD","LU0266013472.USD","LU2089284900.SGD","LLYX","LU0198837287.USD","LU1323610961.USD","LU1127390331.HKD","LU0823434740.USD","LU1267930730.SGD","SGXZ99366536.SGD","LU1069344957.HKD","LU0689472784.USD","IE0004445015.USD","LU2111349929.HKD","LU2491049909.HKD","IE0001KFT4U8.USD","SG9999015986.USD","IE00B775H168.HKD","LU0234572021.USD","GB00BDT5M118.USD","LU0882574139.USD","IE00B2B36J28.USD","LU2108987350.USD","LU0323591593.USD","BK4588","LU0225283273.USD","IE00BKPKM429.USD","SG9999018865.SGD","LU2491050154.USD"],"gpt_icon":0},{"id":"2618157119","title":"FDA 连发多份 CRL，开年大批新药上市申请已遭拒","url":"https://stock-news.laohu8.com/highlight/detail?id=2618157119","media":"制药网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618157119?lang=zh_cn&edition=full","pubTime":"2026-03-11 14:39","pubTimestamp":1773211194,"startTime":"0","endTime":"0","summary":"2026年以来，全球医药企业就遭遇了FDA的CRL风暴。2月14日消息，Disc Medicine备受瞩目的候选药物Bitopertin用于治疗罕见血液病红细胞生成性卟啉症的上市申请遭到FDA拒绝。2月3日，阿斯利康公告称，美国FDA就Saphnelo用于成人系统性红斑狼疮患者皮下给药的生物制品许可申请发出完整答复函，驳回了其狼疮治疗药物的自行注射剂型上市申请。总的来说，2026 年 开年以来，已有众多新药上市申请被拒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AZN","LU0154236417.USD","IE00BZ1G4Q59.USD","LU1093756168.USD","LU1093756325.SGD","NVOH","BK4588","LU0029874061.USD","NVO","IE00BFMHRM44.USD","BK4599","REGN","BK4007","NVOX","LU1815336091.USD","LU0390134368.USD","BK4532","IE00BKVL7J92.USD","BK4585","LU0128526141.USD","BK4121","BK4530","INCY","LU0757428866.USD"],"gpt_icon":0},{"id":"2618918759","title":"Hims & Hers(HIMS.US)挖角礼来公关大将！剑指品牌减肥药新战场","url":"https://stock-news.laohu8.com/highlight/detail?id=2618918759","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618918759?lang=zh_cn&edition=full","pubTime":"2026-03-11 10:22","pubTimestamp":1773195738,"startTime":"0","endTime":"0","summary":"此前，Hims & Hers HealthHims因销售热门减肥药的仿制版本而面临日益增加的法律和监管压力。Hims & Hers Health表示，公司将通过与礼来的主要竞争对手诺和诺德建立新的合作伙伴关系，专注于提供品牌药物。两家公司于周一表示，诺和诺德已同意在Hims & Hers Health平台上销售其王牌药物Ozempic和Wegovy，其中包括备受欢迎的Wegovy口服片剂。同时，诺和诺德将撤回上个月针对Hims & Hers Health提起的诉讼。作为回报，Hims & Hers Health表示将不再为其仿制版诺和诺德药物投放广告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0289739699.SGD","LU2756315318.SGD","LU2361044949.HKD","LU2237438978.USD","LU0354030438.USD","LU1323610961.USD","IE00BWXC8680.SGD","LU0079474960.USD","LU1720051017.SGD","LU0320765992.SGD","LU0097036916.USD","LU1023059063.AUD","LU2089984988.USD","LU2211815571.USD","LU0109391861.USD","LU2456880835.USD","LU2471134796.USD","LU2108987350.USD","LU2361044865.SGD","LU2552382132.HKD","LU2237443895.HKD","IE00BKPKM429.USD","LU0114720955.EUR","LU0061475181.USD","LU2023251221.USD","HIYY","LU2746668974.SGD","LU0225283273.USD","LU2168564222.USD","LU2461242641.AUD","LU1917777945.USD","SG9999014880.SGD","LU0823434583.USD","LU2087625088.SGD","LU0198837287.USD","LU1145028129.USD","SG9999014906.USD","LU0823434740.USD","LU0466842654.USD","LU2111349929.HKD","LU2324357040.USD","LU2750360641.GBP","IE0009355771.USD","IE00BJJMRX11.SGD","IE00BJJMRZ35.SGD","LU0786609619.USD","BK4588","LU1814569148.SGD","LU2462157665.USD","LU2552382058.USD","IE00BJJMRY28.SGD","SG9999001176.SGD","ELIS","LU1551013425.SGD","LU2361045086.USD","LU2417539215.USD","LU0964807845.USD","LU0109394709.USD","LU2089284900.SGD","LU0385154629.USD","LU2089283258.USD","LU1551013342.USD","SGXZ31699556.SGD","BK4196","SGXZ81514606.USD","IE00BJLML261.HKD","LU1974910355.USD","SG9999018865.SGD","LU2271345857.HKD","LU0158827948.USD","SG9999001176.USD","LU0823416689.USD","IE00B1XK9C88.USD","LU2168564495.EUR","LU0417517546.SGD","LU0708995401.HKD","BK4516","LU0787776722.HKD","LU2237443622.USD","LU0353189680.USD","LU1127390331.HKD","LU2028103732.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0203201768.USD","LU0106261372.USD","LU0432979614.USD","LU0689472784.USD","LU1868836591.USD","LU2168564065.EUR","IE00B775H168.HKD","LU0882574055.USD","LU2491050154.USD","HIMS","IE0004445239.USD","LU2360106947.USD","LU2471134879.HKD","LU2471134523.USD","LU0882574139.USD","LU0353189763.USD","LU0122379950.USD","IE00BK4W5M84.HKD","LU1232071149.USD","LU2756315664.SGD","LU1267930730.SGD","LU1069344957.HKD","LU1035775433.USD","LU2896262040.SGD","IE00B2B36J28.USD","LU1983299246.USD","LU0943347566.SGD","LU2491050071.SGD","SG9999015952.SGD","LU0094547139.USD","LU0316494557.USD","LU0203202063.USD","LU1280957306.USD","IE00BFSS7M15.SGD","SG9999017495.SGD","IE00BN29S564.USD","LU0238689110.USD","SG9999015978.USD","SGXZ99366536.SGD","LU0640476718.USD","LU0820562030.AUD","LU1061106388.HKD","LU2213496289.HKD","LU0683600562.USD","SG9999015945.SGD","IE0001KFT4U8.USD","LLYX","IE0005OL40V9.USD","LU2023250330.USD","SG9999015986.USD","LU2265009873.SGD","LU0889565916.HKD","LU1868836757.USD","LU0471298694.HKD","HIMZ","LU2106854487.HKD","BK4534","HIMY","LU2237443465.HKD","BK4007","LU1093756168.USD","LU0006306889.USD","IE0002141913.USD","LU1057294990.SGD","LU1868836914.USD","IE00BJT1NW94.SGD","LU0158827781.USD","LU1629891620.HKD","LU1712237335.SGD","LU0672654240.SGD","LU2023250504.SGD","LU2112291526.USD","SGXZ57979304.SGD","SGXZ51526630.SGD","LU2552382215.SGD","LU1989771016.USD","LU1804176565.USD","HMYY","LLYZ","LU0096364046.USD","LU1548497426.USD","LU2357305700.SGD","LU1064131342.USD","LU2168563687.JPY","LU0256863811.USD","LU2236285917.USD","LU2237443978.SGD","LU1623119135.USD","LU0234572021.USD","LU0256863902.USD","BK4585","IE00BKDWB100.SGD","LU0471298777.SGD","ELIL","LU0354030511.USD","LU0266013472.USD","LU2237443382.USD","LU0323591593.USD","SG9999014898.SGD","SG9999013999.USD","IE00BK4W5L77.USD","LU0210536198.USD","LU2063271972.USD","LU2168564149.EUR","LU0820561909.HKD","LU2602419157.SGD","IE00B4JS1V06.HKD","IE00B7KXQ091.USD","IE00BFSS8Q28.SGD","LU1093756325.SGD","LU0058720904.USD","LU2468319806.SGD","LU1868837136.USD","LU2237443549.SGD","IE0004445015.USD","LU1291159041.SGD","LLII","GB00BDT5M118.USD","LU1868837300.USD","BK4599","LU2746668461.USD","LU2264538146.SGD","LU2471134952.CNY","BK4533","LU1720051108.HKD","BK4581","LU0820561818.USD","LU1988902786.USD","LU1366192091.USD","IE00B1BXHZ80.USD","LU0456855351.SGD","LU2491049909.HKD","SG9999018857.SGD","LU0320765059.SGD","SG9999014914.USD","LU2750360997.AUD"],"gpt_icon":1},{"id":"2618996353","title":"港股异动 | 加科思-B(01167)绩后涨超6% 2025年研发管线多点突破 与阿斯利康共同开发JAB-23E73","url":"https://stock-news.laohu8.com/highlight/detail?id=2618996353","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618996353?lang=zh_cn&edition=full","pubTime":"2026-03-11 09:35","pubTimestamp":1773192931,"startTime":"0","endTime":"0","summary":"截至2025年12月31日，公司拥有380项在全球提交的有效专利或专利申请，其中146项专利已在全球主要市场获颁发或允许。年内，公司与AstraZeneca AB已订立许可与合作协议，共同开发及商业化泛KRAS抑制剂JAB-23E73。根据该许可及合作协议并受其条款及条件所限，北京加科思有权向阿斯利康收取1亿美元的预付款项，并有资格在达成特定开发、监管及商业里程碑时收取额外里程碑付款，总潜在代价最高可达19.15亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412445.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0889565916.HKD","LU2417539215.USD","BK1574","LU2236285917.USD","IE00B3T34201.USD","VXUS","LU1829250122.USD","LU0320765992.SGD","BK4007","BK4585","LU0109394709.USD","01167","BK4568","LU0289739699.SGD","BK4588","AZN","BK1161","LU2462157665.USD","LU0058720904.USD","LU2456880835.USD"],"gpt_icon":0},{"id":"2618963769","title":"诺和诺德旗下“问题”工厂，又一家药企遭殃","url":"https://stock-news.laohu8.com/highlight/detail?id=2618963769","media":"生物制药小编","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618963769?lang=zh_cn&edition=full","pubTime":"2026-03-11 09:20","pubTimestamp":1773192018,"startTime":"0","endTime":"0","summary":"这也是第三家因为该工厂生产设施问题而遭发CRL的药企，其中再生元最为倒霉，2025年，有两款药物皆是因其被拒。2025年10月，同样因为这家工厂的合规性问题，再生元旗下的另一款药物—预填充注射器版本HD Eylea的补充上市申请也遭到拒批，收到FDA的CRL。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311093344a45fc34a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311093344a45fc34a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BKVL7J92.USD","LU1093756325.SGD","NVOX","LU1093756168.USD","BK4585","BK4532","BK4007","NVO","BK4599","LU0154236417.USD","NVOH","BK4588","IE00BZ1G4Q59.USD"],"gpt_icon":1},{"id":"1190586360","title":"Trevi Therapeutics将于2026年3月17日公布2025年第四季度及全年财报并举行业务进展说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=1190586360","media":"美股速递","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190586360?lang=zh_cn&edition=full","pubTime":"2026-03-11 04:07","pubTimestamp":1773173233,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics Inc. (TRVI) 宣布，公司计划于2026年3月17日发布2025年第四季度及全年度的财务业绩报告。届时，管理层还将同步更新公司的最新业务动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRVI"],"gpt_icon":0},{"id":"1193301665","title":"SIGA公布截至2025年12月31日的三个月及全年财务业绩，并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1193301665","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193301665?lang=zh_cn&edition=full","pubTime":"2026-03-11 04:02","pubTimestamp":1773172940,"startTime":"0","endTime":"0","summary":"SIGA Technologies Inc公布了截至2025年12月31日的三个月及全年财务业绩，同时分享了公司最新业务动态。此次披露涵盖关键财务指标与战略发展重点，展现企业在复杂市场环境中的运营韧性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","SIGA","BK4007"],"gpt_icon":0},{"id":"2618968768","title":"Galectin Therapeutics Inc.盘中异动 下午盘急速跳水5.67%报3.16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618968768","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618968768?lang=zh_cn&edition=full","pubTime":"2026-03-11 02:08","pubTimestamp":1773166132,"startTime":"0","endTime":"0","summary":"北京时间2026年03月11日02时08分，Galectin Therapeutics Inc.股票出现异动，股价快速下挫5.67%。截至发稿，该股报3.16美元/股，成交量44.3595万股，换手率0.69%，振幅8.66%。Galectin Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为1.90%。其相关个股中，Polaryx Therapeutics, Inc.、Longeveron Inc.、Cingulate Inc C/Wts 10/12/2026 涨幅较大，Longeveron Inc.、Acurx Pharmaceuticals, Inc.、Biorestorative Therapies, Inc.较为活跃，换手率分别为1100.49%、1003.30%、702.88%，振幅较大的相关个股有Polaryx Therapeutics, Inc.、Longeveron Inc.、Cingulate Inc C/Wts 10/12/2026 ，振幅分别为116.47%、109.01%、60.16%。Galectin Therapeutics Inc.公司简介：Galectin Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031102085297ac610b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031102085297ac610b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GALT","BK4139","LENZ","BK4007","BK4539"],"gpt_icon":0},{"id":"2618691521","title":"Quantum Biopharma Ltd.盘中异动 快速跳水5.36%报3.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618691521","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618691521?lang=zh_cn&edition=full","pubTime":"2026-03-11 00:34","pubTimestamp":1773160447,"startTime":"0","endTime":"0","summary":"北京时间2026年03月11日00时34分，Quantum Biopharma Ltd.股票出现异动，股价急速下跌5.36%。截至发稿，该股报3.18美元/股，成交量2.3159万股，换手率0.60%，振幅5.06%。Quantum Biopharma Ltd.股票所在的生物技术行业中，整体涨幅为1.60%。Quantum Biopharma Ltd.公司简介：Quantum BioPharma Ltd是一家生物制药公司，致力于为具有挑战性的神经退行性疾病和代谢疾病以及酒精滥用疾病的治疗提供创新资产和生物技术解决方案组合，其候选药物处于不同的开发阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311003408a45f0c58&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311003408a45f0c58&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QNTM","BK4007"],"gpt_icon":0},{"id":"2618919079","title":"Alumis Inc.盘中异动 股价大涨5.18%报28.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618919079","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618919079?lang=zh_cn&edition=full","pubTime":"2026-03-11 00:31","pubTimestamp":1773160311,"startTime":"0","endTime":"0","summary":"北京时间2026年03月11日00时31分，Alumis Inc.股票出现波动，股价快速拉升5.18%。截至发稿，该股报28.23美元/股，成交量44.3216万股，换手率0.36%，振幅7.28%。Alumis Inc.股票所在的生物技术行业中，整体涨幅为1.60%。Alumis Inc.公司简介：Alumis Inc 是一家处于临床阶段的生物制药公司，专注于识别、收购并加速开发和商业化用于自身免疫性疾病的变革性药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031100315295474092&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031100315295474092&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2618109952","title":"紧急召回！和黄医药明星抗癌药突遭撤市","url":"https://stock-news.laohu8.com/highlight/detail?id=2618109952","media":"深圳商报·读创","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618109952?lang=zh_cn&edition=full","pubTime":"2026-03-11 00:06","pubTimestamp":1773158781,"startTime":"0","endTime":"0","summary":"3月9日，和黄医药（中国）有限公司（简称“和黄医药”或“本公司”）发布公告，宣布对旗下上市仅满一年的肿瘤创新药他泽司他（商品名：达唯珂?）启动在中国内地、中国香港和中国澳门撤市并召回该产品，同时停止所有正在进行中的他泽司他的临床试验。现有患者应立即咨询主治医生，以讨论治疗选择。公告称，此次撤市预计不会影响本公司的财务指引。2025年，和黄医药的达唯珂?的销售额为250万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603113667856575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","HCM","BK4007","BK4588","BK1587","00013","BK4585","BK4531","BK1588"],"gpt_icon":0},{"id":"2618961479","title":"小红书将打击AI托管账号，豆包内测购物下单功能，SpaceX拟纳斯达克上市，minimax市值达3826.4亿港元，这就是今天的其他大新闻！","url":"https://stock-news.laohu8.com/highlight/detail?id=2618961479","media":"差评","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618961479?lang=zh_cn&edition=full","pubTime":"2026-03-11 00:00","pubTimestamp":1773158400,"startTime":"0","endTime":"0","summary":"SpaceX 希望能够尽早被纳入纳斯达克 100 指数，这被视为其在该交易所上市的必要条件之一。此前报道称，SpaceX 正计划进行IPO，最早可能在 6 月。知情人士表示，SpaceX 此次 IPO 寻求的估值约为 1.75 万亿美元，按最新股价计算，这将使其成为美国市值第六大的公司。minimax 市值达 3826.4 亿港元3 月 10 日，港股上市公司 Minimax 大涨，涨幅超 22%，收盘报价 1220 港元，市值达 3826.4 亿港元，超越百度集团的 3322.2 亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5NDc1NzQ4MA==&mid=2654643799&idx=6&sn=c2692f6ea4b1015c69c367f85699c00b&chksm=8a9bbdce25080210efd32303de4e9dbedb1939c31978141ae7ff2c666e0d42b43e58916a4efa&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["QLD","JEPQ","QQQE","QQQY","QQQJ","NQmain","TSYW.SI",".IXIC","MNQmain","SQQQ","USAW.SI","QYLG","PSQ","UFO","BK1147","USJW.SI","QID","GPIQ","NVIW.SI","BK4007","TQQQ"],"gpt_icon":1},{"id":"2618657669","title":"美国OTC市场Novartis Ag盘中异动 临近午盘股价大跌3.17%报157.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618657669","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618657669?lang=zh_cn&edition=full","pubTime":"2026-03-10 23:59","pubTimestamp":1773158341,"startTime":"0","endTime":"0","summary":"北京时间2026年03月10日23时59分，美国OTC市场Novartis Ag股票出现波动，股价急速下跌3.17%。截至发稿，该股报157.69美元/股，成交量1185股，换手率0.00%，振幅0.00%。美国OTC市场Novartis Ag股票所在的制药行业中，整体跌幅为0.06%。美国OTC市场Novartis Ag公司简介：诺华开发和生产创新药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310235901a6b5dae3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310235901a6b5dae3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NVSEF"],"gpt_icon":0},{"id":"2618954412","title":"当年报披露遭遇商业化品种撤市，和黄医药(00013)何时打破“200亿估值魔咒”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2618954412","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618954412?lang=zh_cn&edition=full","pubTime":"2026-03-10 23:27","pubTimestamp":1773156440,"startTime":"0","endTime":"0","summary":"3月5日，和黄医药披露公司2025年年报业绩，其中公司当期股东应占溢利同比增长1111.03%，表现亮眼。根据财报，在和黄医药当期的4.57亿美元净利润中，有4.16亿美元来自出售上海和黄药业45%股权带来的收益。交易完成后，和黄医药仅持有上海和黄药业5%的股权。而在同一时间，现有品种的撤市，或许成为影响和黄医药估值的一个利空因素。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK4585","BK1587","BK4007","BK4588","HCM","00013","BK4531","BK1588"],"gpt_icon":0},{"id":"2618951442","title":"纳斯达克综合指数涨幅扩大至0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618951442","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618951442?lang=zh_cn&edition=full","pubTime":"2026-03-10 22:56","pubTimestamp":1773154563,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["QQQY","BK4007","QYLG","BK1147","GPIQ","USJW.SI","QLD","QID","MNQmain","SQQQ","HXC","TSYW.SI",".IXIC","QQQM","TQQQ","QQQE","QQQJ","USAW.SI","NVIW.SI","JEPQ","PSQ","NDX","QQQ"],"gpt_icon":0},{"id":"2618991322","title":"Arvinas, Inc.盘中异动 早盘股价大涨7.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618991322","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618991322?lang=zh_cn&edition=full","pubTime":"2026-03-10 21:32","pubTimestamp":1773149578,"startTime":"0","endTime":"0","summary":"北京时间2026年03月10日21时32分，Arvinas, Inc.股票出现波动，股价大幅上涨7.03%。Arvinas, Inc.股票所在的生物技术行业中，整体涨幅为1.36%。Arvinas, Inc.公司简介：Arvinas Inc 是一家临床阶段的生物技术公司，致力于通过发现、开发和商业化降解致病蛋白的疗法，改善罹患衰弱性疾病和危及生命的疾病患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310213258a45ec083&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310213258a45ec083&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARVN","BK4007"],"gpt_icon":0},{"id":"1176827418","title":"SciSparc子公司Neurothera Labs签署最终协议，收购量子临床试验先驱Cliniquantum多数股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1176827418","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176827418?lang=zh_cn&edition=full","pubTime":"2026-03-10 21:28","pubTimestamp":1773149305,"startTime":"0","endTime":"0","summary":"SciSparc Ltd. (SPRC) 宣布，其持股75%的子公司Neurothera Labs已正式签署最终协议，将收购Cliniquantum的多数股权。Cliniquantum是一家专注于量子计算技术应用于临床实验领域的创新公司。此次收购标志着SciSparc在推进创新疗法和临床开发平台方面迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRC","BK4007"],"gpt_icon":0},{"id":"2618895342","title":"Hims & Hers与诺和诺德达成和解","url":"https://stock-news.laohu8.com/highlight/detail?id=2618895342","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618895342?lang=zh_cn&edition=full","pubTime":"2026-03-10 21:03","pubTimestamp":1773147780,"startTime":"0","endTime":"0","summary":"Hims & Hers与诺和诺德结束诉讼，Hims将停止推广复方胰高血糖素样肽-1药物，并通过其平台提供威戈维和奥泽匹克；Hims股价大涨。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-10/doc-inhqphnh6182604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["NVO","LU1093756325.SGD","BK4585","BK4532","IE00BZ1G4Q59.USD","LU0154236417.USD","NVOX","IE00BKVL7J92.USD","NVOH","BK4007","HIMS","LU1093756168.USD","BK4599","BK4588"],"gpt_icon":0},{"id":"1119011859","title":"Citius Oncology公布Lymphir™联合帕博利珠单抗治疗复发或难治性妇科癌研究者发起的1期研究积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1119011859","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119011859?lang=zh_cn&edition=full","pubTime":"2026-03-10 20:48","pubTimestamp":1773146891,"startTime":"0","endTime":"0","summary":"Citius Oncology宣布，其Lymphir™联合帕博利珠单抗治疗复发或难治性妇科癌的研究者发起1期临床试验获得了积极的顶线结果。该研究旨在评估该联合疗法的安全性、耐受性及初步疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","BK4007","BK4139","CTXR"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0046},{"period":"1month","weight":-0.0195},{"period":"3month","weight":-0.0151},{"period":"6month","weight":0.0297},{"period":"1year","weight":0.208},{"period":"ytd","weight":-0.007}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"name":"制药","nameEN":"BK4007"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"制药(BK4007)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供制药(BK4007)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"制药,BK4007,制药股票,制药股票老虎,制药股票老虎国际,制药行情,制药股票行情,制药股价,制药股市,制药股票价格,制药股票交易,制药股票购买,制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"制药(BK4007)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供制药(BK4007)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}